Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting

Journal of Clinical Virology

Volumn 47, Issue 4, 2010, Pages 330-334

  Kiertiburanakul, Sasisopin ^a   Wiboonchutikul, Surasak ^a   Sukasem, Chonlaphat ^a   Chantratita, Wasun ^a   Sungkanuparph, Somnuek ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Etravirine; HIV; Nevirapine; Resistance; Resource limited setting

Indexed keywords

DIDANOSINE; EFAVIRENZ; ETRAVIRINE; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPING COUNTRIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEVIRAPINE; PYRIDAZINES; RETROSPECTIVE STUDIES; THAILAND; TREATMENT OUTCOME;

EID: 77949540555     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.01.018     Document Type: Article

References (23)

1. Beck E.J., Vitoria M., Mandalia S., Crowley S., Gilks C.F., and Souteyrand Y. National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines?. AIDS 20 (2006) 1497-1502
2. Chetchotisakd P., Anunnatsiri S., Kiertiburanakul S., Sutthent R., Anekthananon T., Bowonwatanuwong C., et al. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant. J Int Assoc Physicians AIDS Care (Chicago, IL) 5 (2006) 152-156
3. Marcelin A.G., Jarrousse B., Derache A., Ba M., Dakouo M.L., Doumbia A., et al. HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen. AIDS 21 (2007) 2341-2343
4. Sungkanuparph S., Manosuthi W., Kiertiburanakul S., Piyavong B., Chumpathat N., and Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 44 (2007) 447-452
5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (November 3, 2008), Department of Health and Human Services. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf p. 1-139. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [accessed 12.7.2009]
6. Andries K., Azijn H., Thielemans T., Ludovici D., Kukla M., Heeres J., et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 48 (2004) 4680-4686
7. Johnson V.A., Brun-Vezinet F., Clotet B., Gunthard H.F., Kuritzkes D.R., Pillay D., et al. Update of the drug resistance mutations in HIV-1: spring 2008. Top HIV Med 16 (2008) 62-68
8. Lazzarin A., Campbell T., Clotet B., Johnson M., Katlama C., Moll A., et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370 (2007) 39-48
9. Madruga J.V., Cahn P., Grinsztejn B., Haubrich R., Lalezari J., Mills A., et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370 (2007) 29-38
10. Vingerhoets J., Buelens A., Peeters M., Picchio G., Tambuyzer L., Marck H.V., et al. Impact of baseline NNRTI mutations on the virological response to TMC125 in the phase III clinical trials DUET-1 and DUET-2. Antiviral Ther 12 (2007) S34 [abstract 32]
11. Vingerhoets J., Peeters M., Azijn H., Tambuyzer L., Hoogstoel A., Nijs S., et al. An update of the list of NNRTI mutations associated with decreased virologic response to etravirine (ETR): multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. Antiviral Ther 13 (2008) S3 [Abstract 24]
12. Sungkanuparph S., Manosuthi W., Kiertiburanakul S., Piyavong B., and Chantratita W. Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting. Curr HIV Res 6 (2008) 474-476
13. Lapadula G., Calabresi A., Castelnuovo F., Costarelli S., Quiros-Roldan E., Paraninfo G., et al. Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors. Antivir Ther 13 (2008) 601-605
14. Llibre J.M., Santos J.R., Puig T., Moltó J., Ruiz L., Paredes R., et al. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J Antimicrob Chemother 62 (2008) 909-913
15. Bannistera W.P., Ruizb L., Cozzi-Lepria A., Mocroft A., Kirk O., Staszewski S., et al. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS 22 (2008) 367-376
16. Kagan R.M., Sista P., Pattery T., Bacheler L., and Schwab D.A. Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples. AIDS 23 (2009) 1602-1605
17. Poveda E., Garrido C., de Mendoza C., Corral A., Cobo J., González-Lahoz J., et al. Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 60 (2007) 1409-1410
18. Schiller D.S., Youssef-Bessler M., and Etravirine:. A second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. Clin Ther 31 (2009) 692-704
19. Cotte L., Trabaud M.A., Tardy J.C., Brochier C., Gilibert R.P., Miailhes P., et al. Prediction of the virological response to etravirine in clinical practice: comparison of three genotype algorithms. J Med Virol 81 (2009) 672-677
20. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach (2006 revision). Available at http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf [accessed 3.9.2009].
21. Ruxrungtham K., Pedro R.J., Latiff G.H., Conradie F., Domingo P., Lupo S., et al. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med 9 (2008) 883-896
22. Wirachsilp P., Kantakamalakul W., Foongladda S., Chuenchitra T., Kohriangudom S., Athipanyasilp N., et al. Surveillance of subtype and genetic variation of the circulating strains of HIV-1 in Thailand. Southeast Asian J Trop Med Public Health 38 (2007) 814-827
23. De Mendoza C., Garrido C., Poveda E., Corral A., Zahonero N., Treviño A., et al. Changes in drug resistance patterns following the introduction of HIV type 1 non-B subtypes in Spain. AIDS Res Hum Retroviruses 25 (2009) 967-972